David Bang

David Bang was appointed LifeConEx CEO in 2007 after serving as a founding member and senior vice president of business development and implementation of LifeConEx when it launched as a supplier-neutral joint venture between two cargo powerhouses DHL Global Forwarding (DGF) and Lufthansa Cargo in 2005. Alongside LifeConEx’s top senior management team and board members, David led the 2011 acquisition successfully that made LifeConEx a 100 percent DHL unit.

Since his appointment as CEO, David has spearheaded LifeConEx’s remarkable financial and innovative achievements, positioning the company as a premier globally recognized provider of end-to-end temperature-sensitive logistics management solutions for medicinal products. He has developed a culture that empowers “LifeConExers” to find and apply optimal ways to connect people with life, one shipment at a time. He is dedicated to promoting innovation and high performance culture centered on continuous improvement in all facets of temperature-controlled logistics management.

Based on that foundation, in 2013, David and his team successfully launched DHL THERMONET which is now DGF’s standard temperature controlled freight product tailored to the Life Sciences and Healthcare sector while LifeConEx serves premium segment of the sector. DHL THERMONET is now offered in +90 stations worldwide.

After David finished studying Mechanical Engineering at Northwestern University in Chicago Suburb, he has been with the industry nearly 20 years holding increasingly key positions in global contract acquisition, implementation, sales, finances, IT and strategy. Today, David is an active contributor in numerous trade and technical publications, and frequently speaks at various logistics and life sciences conferences worldwide advocating for reduction of risk, elevated ROI, and ultimate patient safety. In his personal life, he runs half and full marathons and has started learning Spanish. David’s interests also include leadership, innovation, social justice, history and foreign policy. Effective January 2016, David was appointed as a board member for a patient-safety & product integrity advocacy consortium called, Rx-360 (www.rx-360.com).